AvroBio, Inc.
AvroBio, Inc. is listed today as Tectonic Therapeutic, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2025 | $185 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jan 2018 | $61 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jul 2016 | $8 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
AvroBio, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).
SEC Form D · Feb 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2025
That is all the official record says: AvroBio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of AvroBio, Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Atlas Venture Associates X, LLC | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Atlas Venture Associates X, L.P. | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Atlas Venture Fund X, L.P. | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Clarus Lifesciences III, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Clarus Ventures III GP, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Clarus Ventures III, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| SV Life Sciences Fund VI (GP), L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| SV Life Sciences Fund VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| SV Life Sciences Fund VI Strategic Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Svlsf VI, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.
Largest shareholders today
Institutions holding Tectonic Therapeutic, Inc. shares, as of Sep 30, 2026.
- FMR LLC$68 M14.70%
- TCG Crossover Management, LLC$28 M6.04%
- BlackRock, Inc.$20 M4.31%
- Baker Bros. Advisors LP$14 M3.05%
- 5AM Venture Management, LLC$14 M3.04%
- Vanguard Capital Management LLC$12 M2.57%
- First Light Asset Management, LLC$12 M2.49%
- Aberdeen Group plc$11 M2.43%
- Marshall Wace, LLP$10 M2.24%
- Braidwell LP$9 M1.86%
- Vestal Point Capital, LP$8 M1.80%
- Ikarian Capital, LLC$7 M1.54%
- Kennedy Capital Management LLC$7 M1.52%
- Geode Capital Management, LLC$7 M1.42%
- State Street Corp$5 M1.11%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alise Reicin | Executive officer | Feb 2025 |
| Daniel Lochner | Executive officer | Feb 2025 |
| Marc K. Schwabish | Executive officer | Feb 2025 |
| Marcella K. Ruddy | Executive officer | Feb 2025 |
| Peter McNamara | Executive officer | Feb 2025 |
| Christopher Mason | Executive officer | Feb 2018 |
| Deanna Petersen | Executive officer | Feb 2018 |
| Geoffrey MacKay | Executive officer | Feb 2018 |
| Katina Dorton | Executive officer | Feb 2018 |
| Kim Warren | Executive officer | Feb 2018 |
| Alise Reicin | Director | Feb 2025 |
| Phillip B. Donenberg | Director | Feb 2025 |
| Praveen P. Tipirneni | Director | Feb 2025 |
| Stefan P. Vitorovic | Director | Feb 2025 |
| Terrance K. McGuire | Director | Feb 2025 |
| Timothy K. Springer | Director | Feb 2025 |
| Bruce Booth | Director | Feb 2018 |
| Christopher Paige | Director | Feb 2018 |
| Geoffrey MacKay | Director | Feb 2018 |
| Ian Clark | Director | Feb 2018 |
| Joshua Resnick | Director | Feb 2018 |
| Scott Requadt | Director | Feb 2018 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.